Discovery and characterization of potential drivers of resistance to the KRAS G12D inhibitor, MRTX1133, in cancer cell line models

被引：0
|
作者：
Helu, Xousaen M.
Griffiths, Ellie
Calinisan, Andrew
Hebbert, Allan
Yan, Larry
Hoffman, Natalie
Trinh, David
Hover, Laura
Fernandez-Banet, Julio
Briere, David M.
Lifset, Ella
Olson, Peter
Christensen, James G.
Hallin, Jill
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-1943
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1943
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Preclinical characterization of LY3962673, an orally bioavailable, highly potent, and selective KRAS G12D inhibitor
    Iyer, Chandrasekar
    Li, Binghui
    Stewart, Trent R.
    Wang, Tao
    Capen, Andrew
    Cavitt, Rachel
    Anderson, Bryan D.
    Bocchinfuso, Wayne
    Zhao, Gaiying
    Rodriguez, Michael J.
    Carballares, Santiago
    Cooke, Andrew
    Bondi, Robert
    Burns, Lee
    Kelamangalath, Lakshmi
    Wallace, Ross
    Kolakowski, Gabrielle
    Henry, James R.
    Si, Chong
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [32] Structure-based drug discovery of MRTX1257: A selective, covalent KRAS G12C inhibitor with oral activity in animal models of cancer
    Marx, Matthew
    Baer, Brian
    Ballard, Joshua
    Blake, James
    Bouhana, Karyn
    Briere, David
    Burgess, Laurence
    Burkhard, Michael
    Chiang, Harrah
    Chicarelli, Mark
    Christensen, James
    Fischer, John
    Hallin, Jill
    Mejia, Macedonio
    Olson, Peter
    Savechenkov, Pavel
    Sudhakar, Niranjan
    Tang, Tony
    Vigers, Guy
    Fell, Jay
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 257
  • [33] Structure-based drug discovery of MRTX1257, a selective, covalent KRAS G12C inhibitor with oral activity in animal models of cancer.
    Marx, Matthew A.
    Baer, Brian R.
    Ballard, Joshua
    Blake, James F.
    Bouhana, Karyn
    Briere, David M.
    Burgess, Laurence E.
    Burkhard, Michael R.
    Chiang, Harrah
    Chicarelli, Mark J.
    Christensen, James G.
    Fischer, John P.
    Hallin, Jill
    Mejia, Macedonia J.
    Olson, Peter
    Savechenkov, Pavel
    Sudhakar, Niranjan
    Tang, Tony P.
    Vigers, Guy P.
    Fell, Jay B.
    MOLECULAR CANCER RESEARCH, 2020, 18 (05) : 67 - 68
  • [34] Combination effect of the KRAS G12D-specific degrader ASP3082 with Cetuximab in xenograft models of colorectal and pancreatic cancer cells with KRAS G12D mutation
    Iguchi, K.
    Nagashima, T.
    Inamura, K.
    Nishizono, Y.
    Yoshinari, T.
    Hayakawa, M.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S86 - S86
  • [35] Exploring the therapeutic potential of precision T-Cell Receptors (TCRs) in targeting KRAS G12D cancer through in vitro development
    Zheng, Weitao
    Jiang, Dong
    Chen, Songen
    Wu, Meiling
    Yan, Baoqi
    Zhai, Jiahui
    Shi, Yunqiang
    Xie, Bin
    Xie, Xingwang
    Hu, Kanghong
    Ma, Wenxue
    ONCOLOGY RESEARCH, 2024, 32 (12) : 1837 - 1850
  • [36] Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations
    Shahnam, Adel
    Davis, Alexander
    Brown, Lauren Julia
    Sullivan, Isaac
    Lin, Kevin
    Ng, Chien
    Yeo, Nicholas
    Kong, Benjamin Y.
    Khoo, Trisha
    Warburton, Lydia
    Da Silva, Ines Pires
    Mullally, William
    Xu, Wen
    O'Byrne, Ken
    Bray, Victoria
    Pal, Abhijit
    Mersaides, Antony
    Itchins, Malinda
    Arulananda, Surein
    Nagrial, Adnan
    Kao, Steven
    Alexander, Marliese
    Lee, Chee Khoon
    Solomon, Benjamin
    John, Thomas
    LUNG CANCER, 2025, 201
  • [37] Novel KRAS G12D degrader ASP3082 demonstrates in vivo, dose-dependent KRAS degradation, KRAS pathway inhibition, and antitumor efficacy in multiple KRAS G12D-mutated cancer models
    Nagashima, Takeyuki
    Yoshinari, Tomohiro
    Nishizono, Yoshihiro
    Tasaki, Mamoru
    Inamura, Kohei
    Ishioka, Hiroki
    Suzuki, Atsushi
    Osaki, Fumio
    Yamanaka, Yosuke
    Hayakawa, Masahiko
    CANCER RESEARCH, 2023, 83 (07)
  • [38] ALTA3263: an oral, KRAS isoform-selective, dual ON/OFF state, non-covalent inhibitor induces regressions across KRAS G12V, G12D, and G12C cancer models
    Wang, T.
    Ibanez, M.
    Yu, K.
    Fan, K.
    Juan, J.
    Perez, M.
    Smith, T.
    Walsh, B.
    Kang, V.
    Tyhonas, J.
    Alvarez, N.
    Tran, J.
    Moorefield, K. S.
    Phimister, A.
    Zhu, X.
    Chi, A.
    Bartberger, M. D.
    Murphy, E.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S5 - S6
  • [39] Treating KRAS(G12D) inhibitor resistance using a KRAS- and HSP90 chaperone-targeted hetero-bispecific small molecule agent
    Pulido, Ines
    Luan, Qiyue
    Yin, Chenghao
    Yang, Zimo
    Lin, Jinhua
    Wang, Yaya
    Sun, Yuetong
    Liu, Chuche
    Zhou, Haoxin
    Massad, Marek
    Papautsky, Ian
    Prince, Thomas L.
    Wang, Guoqiang
    Foley, Kevin P.
    Ying, Weiwen
    Shimamura, Takeshi
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [40] Enhancing KRAS G12D inhibitor sensitivity in pancreatic cancer through SHP2/PI3K pathway
    Hao, Man-Wei
    Zhang, Tian-Xing
    Dong, Dan
    Zhou, Xin
    Gao, Haicheng
    MEDICAL ONCOLOGY, 2025, 42 (05)
12345